Participant flow

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants randomized to asciminib 40mg BID

   id

   FG000

   title

   Asciminib

2. description

   Participants randomized to bosutinib 500mg QD

   id

   FG001

   title

   Bosutinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         40

      2. group Id

         FG001

         num Subjects

         28

      type

      Lack of Efficacy

   2. reasons

      1. group Id

         FG000

         num Subjects

         13

      2. group Id

         FG001

         num Subjects

         7

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         21

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         7

      type

      Subject/Guardian Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         0

      type

      Death

   6. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         3

      type

      Progressive Disease

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         2

      type

      Lost to Follow-up

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Pregnancy

   9. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Protocol Violation

   10. reasons

       1. group Id

          FG000

          num Subjects

          1

       2. group Id

          FG001

          num Subjects

          0

       type

       Not treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         157

      2. group Id

         FG001

         num Subjects

         76

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         156

      2. group Id

         FG001

         num Subjects

         76

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      comment

      One participant randomized to asciminib was discontinued due to cytopenia as per Investigator's decision and never took medication.

      type

      Not Treated

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         25

      type

      Switched to Receive Asciminib

   5. achievements

      1. group Id

         FG000

         num Subjects

         77

      2. group Id

         FG001

         num Subjects

         8

      comment

      Completed = Completed Treatment

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         80

      2. group Id

         FG001

         num Subjects

         68

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Randomization was stratified by major cytogenetic response (MCyR) at screening.

recruitment Details

Participants were treated at a total of 84 sites.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice